Immunovant Inc
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating p… Read more
Market Cap & Net Worth: Immunovant Inc (IMVT)
Immunovant Inc (NASDAQ:IMVT) has a market capitalization of $5.11 Billion ($5.11 Billion) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #4663 globally and #2893 in its home market, demonstrating a -4.96% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Immunovant Inc's stock price $25.10 by its total outstanding shares 203532180 (203.53 Million).
Immunovant Inc Market Cap History: 2019 to 2026
Immunovant Inc's market capitalization history from 2019 to 2026. Data shows growth from $3.23 Billion to $5.11 Billion (14.71% CAGR).
Index Memberships
Immunovant Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.10% | #123 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.01% | #570 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.54 Trillion | 0.15% | #76 of 263 |
Weight: Immunovant Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Immunovant Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Immunovant Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of IMVT by Market Capitalization
Companies near Immunovant Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Immunovant Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Immunovant Inc Historical Marketcap From 2019 to 2026
Between 2019 and today, Immunovant Inc's market cap moved from $3.23 Billion to $ 5.11 Billion, with a yearly change of 14.71%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $5.11 Billion | -1.26% |
| 2025 | $5.17 Billion | +2.62% |
| 2024 | $5.04 Billion | -41.21% |
| 2023 | $8.57 Billion | +137.35% |
| 2022 | $3.61 Billion | +108.33% |
| 2021 | $1.73 Billion | -81.55% |
| 2020 | $9.40 Billion | +191.05% |
| 2019 | $3.23 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Immunovant Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.11 Billion USD |
| MoneyControl | $5.11 Billion USD |
| MarketWatch | $5.11 Billion USD |
| marketcap.company | $5.11 Billion USD |
| Reuters | $5.11 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.